Audrey Greenberg is named to the Titan 100 list for the second time, earning the honor last year, just one in a remarkable string of accomplishments for the entrepreneur and her company, Center for Breakthrough Medicines (CBM).
In 2022, Center for Breakthrough Medicines raised $350 million, hired 300 people and signed a $100 million sponsored research agreement with the Gene Therapy Program at University of Pennsylvania. The company also won Employer of the Year with BioBuzz, Innovator of the Year with Inno at Philadelphia Business Journal, Startup of the Year with Philadelphia Alliance for Capital and Technology Enterprise Awards, and Diversity, Equity and Inclusion Initiative of the Year for the Advanced Therapy Awards at Phacilitate.
Greenberg was recognized as a Woman of Distinction by the Philly Business Journal, the Philadelphia Power 100 by the Business Journal and Healthcare Power Player.
“I would say my greatest accomplishment is steering the company through an incredibly challenging business environment steeped in supply chain constraints, rising inflation and tightening capital markets,” Greenberg said. “CBM’s ability to be nimble while capitalizing on market disruption allowed us to capture the future need of customers and the market.
“I am also quite proud of our ability to respond to current workforce demands, allowing each employee to bring their true authentic selves to work, whether it be virtual or in person. We also have a concerted effort to have our workforce reflect the society we live in with diversity, equity and inclusion at the epicenter.”
The mission at Center for Breakthrough Medicines is to accelerate the development and manufacturing of cell and gene therapies. CBM is a cell and gene therapy contract development and manufacturing organization positioned to enable pharma and biotech companies to develop, test and manufacture lifesaving therapies and treatments on a global scale, the company said.
“This year will be about stretching capital dollars, being prudent with hiring and working on revenue-generating activities,” the company said. “The capital market turbulence in 2022 forced biotech companies to re-prioritize their pipelines, delay clinical trials due to COVID and stretch their capital further due to lack of available capital. Companies that service this sector saw their total addressable markets shrink, but those that adapted to the market environment quickly saw a positive impact. CBM hired, built massive capacity and deployed digital modalities to create a best-in-class platform to meet market demand.
“We created a lead-generation machine supported by a robust digital marketing backbone to optimize our customer funnel leading to pipeline success. Our strategic partnerships were strengthened, including an announced venture with University of Pennsylvania’s Gene Therapy Program, an automation program with Autolomus and various customer partnerships, including Achilles, Iecure and other well-known cell and gene therapy innovators from around the world. We are looking forward to what 2023 brings!”
